Genzyme Targets Sandoz Over Kidney Drug ANDA
Sandoz Inc., the generics arm of Novartis AG, is facing a patent infringement suit from Genzyme Corp. over an abbreviated new drug application for an off-brand version of kidney disease treatment...To view the full article, register now.
Already a subscriber? Click here to view full article